KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer

(MedPage Today) -- Integrating checkpoint blockade with pembrolizumab (Keytruda) into standard concurrent chemoradiotherapy plus brachytherapy significantly improved progression-free survival in cervical cancer and showed an early trend toward...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news